IOP

Beijing, China
Beijing, China
SEARCH FILTERS
Time filter
Source Type

News Article | May 23, 2017
Site: www.marketwired.com

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Convalo Health International, Corp. ("Convalo" or the "Company") (TSX VENTURE:CXV), a leading company in the United States addiction recovery industry, today announced it has executed a management services agreement ("MSA") with an operating partner to operate the Company's 18-bed detox and residential center located in the heart of Hollywood, California. Since executing the MSA earlier in May, the operating partner has increased census by over 90%. The financial impact of these results will only begin to be reflected in May 2017, the third month of the first fiscal quarter. No additional corporate overhead has been incurred by Convalo as a result of executing the MSA. This MSA is another example of Convalo implementing its new strategy. The operating partner has been in the addiction treatment industry for many years and specializes in marketing specifically to residential and detox patients. Previously, the partner's business model centered only on helping detox centers source potential patients, rather than benefiting from operating their own center. With the new partnership, the operating partner has now turned its resources to filling the 18 bed center and has expressed interest in operating further residential and detox centers once the relationship has developed with Convalo. "This experience with our new operating partner is an example of the leverage we can achieve with our new strategy," said Chris Heath, CEO of Convalo. "Since taking over the residential center, they have increased patient enrollment quickly and significantly, bringing census from about one third to about two thirds full in a matter of weeks. I believe with their background and expertise, we could see a near capacity center there soon. We have moved all payroll and associated operating costs from Convalo's responsibility to that of the operating partner, reducing operating costs for the month of May. These costs savings will be most visible in our second quarter ending in August, when those savings could be achieved in each month of the quarter. My team and I continue to look for new operating partners since changing our model earlier in the year. All things being equal, we have the cash on the balance sheet to double our revenues." Convalo has shifted to a strategy of decentralizing treatment operations, including sales and marketing functions. The majority of the current location's management and staffing decisions, including sales and marketing, now reside with a local leadership team at each individual center through an MSA. Convalo is shifting the clinical and operational staff management and hiring at each individual center, as well as the majority of the sales and marketing responsibilities of the clinics, to the local general managers and outreach leaders through an MSA, enabling these leaders to make cost decisions independently. The model allows local operators to keep some of the annual cash flow generated from their operations and aligns incentives between the Company and the operators. These leaders, the majority of whom have already executed an MSA, have been established at the current seven sites, in some cases for as long as two years. Because of the previous "centralized" management model, they were restricted from hiring local staff and managing the center as a "stand alone" or decentralized model. Further, they were not incentivized to use local marketing techniques, which are often a fraction of the cost of national advertising. The previous management team attempted to centralize all aspects of the centers, from staffing and back office to sales and marketing, resulting in expenditure of a tremendous amount of time, energy and money without commensurate rewards in revenue growth. "With the new model," explained Mr. Heath, "we should be able to expand more rapidly and limit our risk if one of our partners underperforms." Under the new model, Convalo will continue to own or lease its existing facilities (depending on the market) and provide branding support, facilities (real estate, furniture, fixtures and equipment) management and upkeep, call center services, clinical protocols, and documentation support to all centers. Convalo will continue to maintain control of these facilities in the event a change in local management is someday needed. For new facilities, Convalo will have the flexibility to decide whether to own or lease, and management will focus upon speed to profitability and return on equity in deciding upon the proper structure. Convalo will shift corporate ownership costs at new locations to the local operational and outreach leaders, incentivizing them like partners instead of employees. As part of incentives for the new team, the Board issued 100,000 options to Mr. Jason Monroe as COO. In addition, the Board issued 1,400,000 options to parties at Convalo that are key to the success of the new business model. All options have a strike price of $0.165, vest 1/3 each in May 2018, 2019 and 2020 respectively, and have a 10-year exercise provision. Convalo, operating under the brand name BLVD Centers (www.blvdcenters.com), is a leader in the highly fragmented addiction rehabilitation market. Led by a new executive management team, Convalo is well positioned for continued national expansion by launching pods in cities across the United States. A pod consists of a residential, detox, and mental health facility (detox facility) and an intensive outpatient (IOP) facility. Convalo, under the BLVD brand, is focused upon becoming the largest national provider of a range of mental health services, including addictive and co-occurring disorders. In conjunction with the long standing 12-Step approach, BLVD also offers supplemental insurance-reimbursed services catering to a variety of communities: gender specific, creatively-oriented, meditation/mindfulness, trauma and LGBT affirmative. Certain statements contained in this press release constitute "forward-looking information" as such term is defined in applicable Canadian securities legislation. The words "may", "would", "could", "should", "potential", "will", "seek", "intend", "plan", "anticipate", "believe", "estimate", "expect" and similar expressions as they relate to the Company, near capacity patient enrollment soon at the Hollywood detox and residential center, costs savings in the second quarter, expanding more rapidly and limiting risk under the new model, and the Company shifting corporate ownership costs to the local operational and outreach leaders, incentivizing them like partners instead of employees, are intended to identify forward-looking information. All statements other than statements of historical fact may be forward-looking information. Such statements reflect the Company's current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions. Material factors or assumptions were applied in providing forward-looking information, including: insurance reimbursement remains at levels similar to today, census levels and patient demand remains strong, partners operate their locations profitably, partners reimburse the Company for any and all working capital loans, additional corporate overhead is not needed). Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking information to vary from those described herein should one or more of these risks or uncertainties materialize. These factors include, without limitation, changes in law, the ability to implement business strategies and pursue business opportunities, state of the capital markets, the availability of funds and resources to pursue operations, decline of reimbursement rates, dependence on few payors, possible new drug discoveries, a novel business model, dependence on key suppliers, granting of permits and licenses in a highly regulated business, competition, difficulty integrating newly acquired businesses, the outcome and cost of any litigation with insurance providers, low profit market segments, as well as general economic, market and business conditions, as well as those risk factors discussed or referred to in Convalo's annual Management's Discussion and Analysis for the year ended February 29, 2016, filed with the securities regulatory authorities in certain provinces of Canada and available at www.sedar.com. Should any factor affect Convalo in an unexpected manner, or should assumptions underlying the forward looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, Convalo does not assume responsibility for the accuracy or completeness of such forward-looking information. The forward -looking information included in this press release is made as of the date of this press release and Convalo undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law. Convalo's results and forward-looking information and calculations may be affected by fluctuations in exchange rates. All figures are in Canadian dollars unless otherwise indicated.


9 mai 2017   Sophia Antipolis, France   Nicox S.A. (Euronext Paris : FR0013018124, COX, éligible PEA-PME), société internationale de R&D spécialisée en ophtalmologie, annonce aujourd'hui la présentation d'un poster montrant des résultats scientifiques pour le NCX 667, un nouveau composé donneur d'oxyde nitrique (NO), au congrès annuel 2017 de l' Association for Research in Vision and Ophthalmology (ARVO), l'un des congrès scientifiques de référence en ophtalmologie, qui se tient du 7 au 11 mai 2017 à Baltimore, Maryland, Etats-Unis.   Le NCX 667, molécule synthétisée par Nicox, est le composé leader le plus avancé d'une nouvelle classe de donneurs d'oxyde nitrique purs de nouvelle génération conçus pour optimiser la dose d'oxyde nitrique délivrée après administration en monothérapie ou combinée avec des traitements standard, pour réduire la pression intraoculaire (PIO) de façon significative chez des patients atteints de glaucome à angle ouvert ou d'hypertension oculaire.   L'abstract du Dr. Elena Bastia, et al à l'ARVO 2017 présente des résultats non cliniques obtenus dans des modèles d'hypertension oculaire et de glaucome chez le lapin et des primates non humains après administration répétée de NCX 667. Les résultats démontrent une réduction rapide et prolongée de la PIO sans signes de tachyphylaxie ou d'inconfort oculaire. Le Dr. Michael Bergamini, Directeur Scientifique et Vice-président Exécutif de Nicox, commente : "Un grand nombre de données expérimentales et cliniques étayent le rôle de l'oxyde nitrique dans la réduction de la pression intraoculaire en augmentant l'écoulement de l'humeur aqueuse grâce à la relaxation du réseau trabéculaire et du canal de Schlemm. Le NCX 667 est un nouveau composé donneur d'oxyde nitrique avec lequel il a été démontré une réduction significative de la pression intraoculaire chez le lapin et des primates non humains après une seule administration. Les données présentées à l'ARVO cette année démontrent que, indépendamment du modèle expérimental utilisé, une administration répétée du NCX 667 réduit de façon régulière la pression intraoculaire pendant plusieurs jours d'administration, en maintenant une efficacité avec une absence de signes d'inconfort oculaire." Le glaucome à angle ouvert est une pathologie oculaire fréquente affectant environ 2% de la population adulte de plus de 40 ans. Il est la deuxième cause de cécité dans le monde1. Les abstracts de l'ARVO 2017 ont été publiés sur le site du congrès : www.arvo.org/AM/Program. Les informations relatives à la présentation du poster sont les suivantes :   Titre : "Repeated dosing of NCX 667, a new nitric oxide (NO) donor, retains IOP-lowering activity in animal models of glaucoma" Date : Lundi 8 mai 2017 de 15h45 à 17h30, heure locale Présentation : Elena Bastia, Institut de Recherche Nicox Session : Clinical trials and drug studies Abstract n°2106, Poster n°A0167 Lieu : Congrès annuel 2017 de l'ARVO à Baltimore, Maryland, Etats-Unis   A propos du NCX 667 De précédents résultats prometteurs dans deux modèles précliniques d'hypertension oculaire et de glaucome ont été présentés aux congrès 2015 et 2016 de l'ARVO. Dans les deux modèles, le NCX 667 s'est révélé bien toléré et efficaces dans la réduction de la pression intraoculaire. En 2015, des résultats ont été choisis par le comité d'organisation du congrès de l'ARVO comme "sujet d'intérêt" (Hot Topic), une sélection saluant les travaux de recherche les plus récents et innovants.   Notes:   1.    Glaucoma, Open-angle - https://nei.nih.gov/eyedata/glaucoma, accessed February 13, 2017


9 mai 2017   Sophia Antipolis, France   Nicox S.A. (Euronext Paris : FR0013018124, COX, éligible PEA-PME), société internationale de R&D spécialisée en ophtalmologie, annonce aujourd'hui la présentation d'un poster montrant des résultats scientifiques pour le NCX 667, un nouveau composé donneur d'oxyde nitrique (NO), au congrès annuel 2017 de l' Association for Research in Vision and Ophthalmology (ARVO), l'un des congrès scientifiques de référence en ophtalmologie, qui se tient du 7 au 11 mai 2017 à Baltimore, Maryland, Etats-Unis.   Le NCX 667, molécule synthétisée par Nicox, est le composé leader le plus avancé d'une nouvelle classe de donneurs d'oxyde nitrique purs de nouvelle génération conçus pour optimiser la dose d'oxyde nitrique délivrée après administration en monothérapie ou combinée avec des traitements standard, pour réduire la pression intraoculaire (PIO) de façon significative chez des patients atteints de glaucome à angle ouvert ou d'hypertension oculaire.   L'abstract du Dr. Elena Bastia, et al à l'ARVO 2017 présente des résultats non cliniques obtenus dans des modèles d'hypertension oculaire et de glaucome chez le lapin et des primates non humains après administration répétée de NCX 667. Les résultats démontrent une réduction rapide et prolongée de la PIO sans signes de tachyphylaxie ou d'inconfort oculaire. Le Dr. Michael Bergamini, Directeur Scientifique et Vice-président Exécutif de Nicox, commente : "Un grand nombre de données expérimentales et cliniques étayent le rôle de l'oxyde nitrique dans la réduction de la pression intraoculaire en augmentant l'écoulement de l'humeur aqueuse grâce à la relaxation du réseau trabéculaire et du canal de Schlemm. Le NCX 667 est un nouveau composé donneur d'oxyde nitrique avec lequel il a été démontré une réduction significative de la pression intraoculaire chez le lapin et des primates non humains après une seule administration. Les données présentées à l'ARVO cette année démontrent que, indépendamment du modèle expérimental utilisé, une administration répétée du NCX 667 réduit de façon régulière la pression intraoculaire pendant plusieurs jours d'administration, en maintenant une efficacité avec une absence de signes d'inconfort oculaire." Le glaucome à angle ouvert est une pathologie oculaire fréquente affectant environ 2% de la population adulte de plus de 40 ans. Il est la deuxième cause de cécité dans le monde1. Les abstracts de l'ARVO 2017 ont été publiés sur le site du congrès : www.arvo.org/AM/Program. Les informations relatives à la présentation du poster sont les suivantes :   Titre : "Repeated dosing of NCX 667, a new nitric oxide (NO) donor, retains IOP-lowering activity in animal models of glaucoma" Date : Lundi 8 mai 2017 de 15h45 à 17h30, heure locale Présentation : Elena Bastia, Institut de Recherche Nicox Session : Clinical trials and drug studies Abstract n°2106, Poster n°A0167 Lieu : Congrès annuel 2017 de l'ARVO à Baltimore, Maryland, Etats-Unis   A propos du NCX 667 De précédents résultats prometteurs dans deux modèles précliniques d'hypertension oculaire et de glaucome ont été présentés aux congrès 2015 et 2016 de l'ARVO. Dans les deux modèles, le NCX 667 s'est révélé bien toléré et efficaces dans la réduction de la pression intraoculaire. En 2015, des résultats ont été choisis par le comité d'organisation du congrès de l'ARVO comme "sujet d'intérêt" (Hot Topic), une sélection saluant les travaux de recherche les plus récents et innovants.   Notes:   1.    Glaucoma, Open-angle - https://nei.nih.gov/eyedata/glaucoma, accessed February 13, 2017


News Article | May 9, 2017
Site: globenewswire.com

May 9, 2017   Sophia Antipolis, France   Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, today announced a poster presentation highlighting scientific data for NCX 667, a novel nitric oxide (NO) donating compound, at the Association for Research in Vision and Ophthalmology (ARVO) 2017 Annual Meeting, one of the key scientific events in the ophthalmology calendar, being held May 7-11, 2017 in Baltimore, Maryland, United States.  Synthesized by Nicox, NCX 667 is the lead compound of a new class of next-generation stand-alone NO donors, which is designed to optimize NO dosing when administered alone or in combination with standard-of-care treatments to enable robust intraocular pressure (IOP)-lowering in patients with open-angle glaucoma or ocular hypertension. The ARVO 2017 abstract by Dr. Elena Bastia, et al. describes preclinical results obtained following repeated dosing with NCX 667 in rabbit and non-human primate models of ocular hypertension and glaucoma.  The data demonstrate rapid and sustained IOP lowering with no signs of tachyphylaxis or ocular discomfort. Dr. Michael Bergamini, Chief Scientific Officer and Executive Vice President at Nicox, commented: "A wealth of experimental and clinical data support the role of NO in lowering IOP by increasing aqueous humor outflow through relaxation of the trabecular meshwork and Schlemm's canal.  NCX 667 is a novel NO donor that has been shown to effectively lower IOP in rabbit and non-human primate models following single administration.  The data presented at ARVO this year demonstrate that regardless of the experimental paradigm used, repeated dosing with NCX 667 consistently lowers IOP over several days of dosing, maintaining efficacy while lacking signs of ocular discomfort." Open-angle glaucoma is a common ocular disorder affecting around 2% of the adult population over 40 years old and is the second-leading cause of blindness worldwide1. The ARVO 2017 abstracts have been published in the meeting website located at www.arvo.org/AM/Program/ and details for the poster presentation are as follows:   Title: Repeated dosing of NCX 667, a new nitric oxide (NO) donor, retains IOP-lowering activity in animal models of glaucoma Date and time: Monday May 8, 2017 from 3:45pm to 5:30pm ET Presenter: Elena Bastia, Nicox Research Institute   Session: Clinical trials and drug studies Abstract n° 2106, Poster n° A0167 Location: 2017 ARVO Annual Meeting, Baltimore, Maryland (USA)           About NCX 667   Previous promising results in two preclinical models of ocular hypertension and glaucoma were presented at ARVO in 2015 and 2016.  In both models, NCX 667 appeared well-tolerated and effective in reducing IOP.  In 2015, results were selected by the ARVO Annual Meeting Program Committee as a 'Hot Topic', representing the newest and most innovative research being conducted. Notes: 1. Glaucoma, Open-angle - https://nei.nih.gov/eyedata/glaucoma, accessed February 13, 2017


News Article | May 9, 2017
Site: globenewswire.com

May 9, 2017   Sophia Antipolis, France   Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, today announced a poster presentation highlighting scientific data for NCX 667, a novel nitric oxide (NO) donating compound, at the Association for Research in Vision and Ophthalmology (ARVO) 2017 Annual Meeting, one of the key scientific events in the ophthalmology calendar, being held May 7-11, 2017 in Baltimore, Maryland, United States.  Synthesized by Nicox, NCX 667 is the lead compound of a new class of next-generation stand-alone NO donors, which is designed to optimize NO dosing when administered alone or in combination with standard-of-care treatments to enable robust intraocular pressure (IOP)-lowering in patients with open-angle glaucoma or ocular hypertension. The ARVO 2017 abstract by Dr. Elena Bastia, et al. describes preclinical results obtained following repeated dosing with NCX 667 in rabbit and non-human primate models of ocular hypertension and glaucoma.  The data demonstrate rapid and sustained IOP lowering with no signs of tachyphylaxis or ocular discomfort. Dr. Michael Bergamini, Chief Scientific Officer and Executive Vice President at Nicox, commented: "A wealth of experimental and clinical data support the role of NO in lowering IOP by increasing aqueous humor outflow through relaxation of the trabecular meshwork and Schlemm's canal.  NCX 667 is a novel NO donor that has been shown to effectively lower IOP in rabbit and non-human primate models following single administration.  The data presented at ARVO this year demonstrate that regardless of the experimental paradigm used, repeated dosing with NCX 667 consistently lowers IOP over several days of dosing, maintaining efficacy while lacking signs of ocular discomfort." Open-angle glaucoma is a common ocular disorder affecting around 2% of the adult population over 40 years old and is the second-leading cause of blindness worldwide1. The ARVO 2017 abstracts have been published in the meeting website located at www.arvo.org/AM/Program/ and details for the poster presentation are as follows:   Title: Repeated dosing of NCX 667, a new nitric oxide (NO) donor, retains IOP-lowering activity in animal models of glaucoma Date and time: Monday May 8, 2017 from 3:45pm to 5:30pm ET Presenter: Elena Bastia, Nicox Research Institute   Session: Clinical trials and drug studies Abstract n° 2106, Poster n° A0167 Location: 2017 ARVO Annual Meeting, Baltimore, Maryland (USA)           About NCX 667   Previous promising results in two preclinical models of ocular hypertension and glaucoma were presented at ARVO in 2015 and 2016.  In both models, NCX 667 appeared well-tolerated and effective in reducing IOP.  In 2015, results were selected by the ARVO Annual Meeting Program Committee as a 'Hot Topic', representing the newest and most innovative research being conducted. Notes: 1. Glaucoma, Open-angle - https://nei.nih.gov/eyedata/glaucoma, accessed February 13, 2017


9 mai 2017   Sophia Antipolis, France   Nicox S.A. (Euronext Paris : FR0013018124, COX, éligible PEA-PME), société internationale de R&D spécialisée en ophtalmologie, annonce aujourd'hui la présentation d'un poster montrant des résultats scientifiques pour le NCX 667, un nouveau composé donneur d'oxyde nitrique (NO), au congrès annuel 2017 de l' Association for Research in Vision and Ophthalmology (ARVO), l'un des congrès scientifiques de référence en ophtalmologie, qui se tient du 7 au 11 mai 2017 à Baltimore, Maryland, Etats-Unis.   Le NCX 667, molécule synthétisée par Nicox, est le composé leader le plus avancé d'une nouvelle classe de donneurs d'oxyde nitrique purs de nouvelle génération conçus pour optimiser la dose d'oxyde nitrique délivrée après administration en monothérapie ou combinée avec des traitements standard, pour réduire la pression intraoculaire (PIO) de façon significative chez des patients atteints de glaucome à angle ouvert ou d'hypertension oculaire.   L'abstract du Dr. Elena Bastia, et al à l'ARVO 2017 présente des résultats non cliniques obtenus dans des modèles d'hypertension oculaire et de glaucome chez le lapin et des primates non humains après administration répétée de NCX 667. Les résultats démontrent une réduction rapide et prolongée de la PIO sans signes de tachyphylaxie ou d'inconfort oculaire. Le Dr. Michael Bergamini, Directeur Scientifique et Vice-président Exécutif de Nicox, commente : "Un grand nombre de données expérimentales et cliniques étayent le rôle de l'oxyde nitrique dans la réduction de la pression intraoculaire en augmentant l'écoulement de l'humeur aqueuse grâce à la relaxation du réseau trabéculaire et du canal de Schlemm. Le NCX 667 est un nouveau composé donneur d'oxyde nitrique avec lequel il a été démontré une réduction significative de la pression intraoculaire chez le lapin et des primates non humains après une seule administration. Les données présentées à l'ARVO cette année démontrent que, indépendamment du modèle expérimental utilisé, une administration répétée du NCX 667 réduit de façon régulière la pression intraoculaire pendant plusieurs jours d'administration, en maintenant une efficacité avec une absence de signes d'inconfort oculaire." Le glaucome à angle ouvert est une pathologie oculaire fréquente affectant environ 2% de la population adulte de plus de 40 ans. Il est la deuxième cause de cécité dans le monde1. Les abstracts de l'ARVO 2017 ont été publiés sur le site du congrès : www.arvo.org/AM/Program. Les informations relatives à la présentation du poster sont les suivantes :   Titre : "Repeated dosing of NCX 667, a new nitric oxide (NO) donor, retains IOP-lowering activity in animal models of glaucoma" Date : Lundi 8 mai 2017 de 15h45 à 17h30, heure locale Présentation : Elena Bastia, Institut de Recherche Nicox Session : Clinical trials and drug studies Abstract n°2106, Poster n°A0167 Lieu : Congrès annuel 2017 de l'ARVO à Baltimore, Maryland, Etats-Unis   A propos du NCX 667 De précédents résultats prometteurs dans deux modèles précliniques d'hypertension oculaire et de glaucome ont été présentés aux congrès 2015 et 2016 de l'ARVO. Dans les deux modèles, le NCX 667 s'est révélé bien toléré et efficaces dans la réduction de la pression intraoculaire. En 2015, des résultats ont été choisis par le comité d'organisation du congrès de l'ARVO comme "sujet d'intérêt" (Hot Topic), une sélection saluant les travaux de recherche les plus récents et innovants.   Notes:   1.    Glaucoma, Open-angle - https://nei.nih.gov/eyedata/glaucoma, accessed February 13, 2017


News Article | May 9, 2017
Site: globenewswire.com

May 9, 2017   Sophia Antipolis, France   Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, today announced a poster presentation highlighting scientific data for NCX 667, a novel nitric oxide (NO) donating compound, at the Association for Research in Vision and Ophthalmology (ARVO) 2017 Annual Meeting, one of the key scientific events in the ophthalmology calendar, being held May 7-11, 2017 in Baltimore, Maryland, United States.  Synthesized by Nicox, NCX 667 is the lead compound of a new class of next-generation stand-alone NO donors, which is designed to optimize NO dosing when administered alone or in combination with standard-of-care treatments to enable robust intraocular pressure (IOP)-lowering in patients with open-angle glaucoma or ocular hypertension. The ARVO 2017 abstract by Dr. Elena Bastia, et al. describes preclinical results obtained following repeated dosing with NCX 667 in rabbit and non-human primate models of ocular hypertension and glaucoma.  The data demonstrate rapid and sustained IOP lowering with no signs of tachyphylaxis or ocular discomfort. Dr. Michael Bergamini, Chief Scientific Officer and Executive Vice President at Nicox, commented: "A wealth of experimental and clinical data support the role of NO in lowering IOP by increasing aqueous humor outflow through relaxation of the trabecular meshwork and Schlemm's canal.  NCX 667 is a novel NO donor that has been shown to effectively lower IOP in rabbit and non-human primate models following single administration.  The data presented at ARVO this year demonstrate that regardless of the experimental paradigm used, repeated dosing with NCX 667 consistently lowers IOP over several days of dosing, maintaining efficacy while lacking signs of ocular discomfort." Open-angle glaucoma is a common ocular disorder affecting around 2% of the adult population over 40 years old and is the second-leading cause of blindness worldwide1. The ARVO 2017 abstracts have been published in the meeting website located at www.arvo.org/AM/Program/ and details for the poster presentation are as follows:   Title: Repeated dosing of NCX 667, a new nitric oxide (NO) donor, retains IOP-lowering activity in animal models of glaucoma Date and time: Monday May 8, 2017 from 3:45pm to 5:30pm ET Presenter: Elena Bastia, Nicox Research Institute   Session: Clinical trials and drug studies Abstract n° 2106, Poster n° A0167 Location: 2017 ARVO Annual Meeting, Baltimore, Maryland (USA)           About NCX 667   Previous promising results in two preclinical models of ocular hypertension and glaucoma were presented at ARVO in 2015 and 2016.  In both models, NCX 667 appeared well-tolerated and effective in reducing IOP.  In 2015, results were selected by the ARVO Annual Meeting Program Committee as a 'Hot Topic', representing the newest and most innovative research being conducted. Notes: 1. Glaucoma, Open-angle - https://nei.nih.gov/eyedata/glaucoma, accessed February 13, 2017


Dr. John A. Francis Recognized as a Professional of the Year by Strathmore's Who's Who Worldwide Publication Lees Summit, MO, May 12, 2017 --( About Dr. John A. Francis Dr. Francis is the President and Medical Director of Kansas City Psychiatric & Psychological Services, LLC. KCPPS is a multidisciplinary mental health facility providing an intense outpatient mental health program in Lees Summit, Missouri. With 14 years experience, he oversees the practice and teaches medical students. Dr. Francis provides psychiatric treatment to children, adolescents, and adults. He has specialized training and expertise in treating PTSD, OCD, and severe persistent mental illness of many varieties. He is Board Certified in Psychiatry and affiliated with the American Psychiatric Association. Since starting in private practice, Dr. Francis has endeavored to make patient care effectual, practical and affordable. In 2007, along with his therapist partner, he formed KCPPS which has been a regional leader in innovative treatments and a leader in implementing contemporary and cost effective treatment models. Their Intensive Outpatient Programs have, since their inception, utilized a “therapy first” model, highlighting the paramount importance of the therapist in the patient’s overall treatment. Their IOP modules address Dual Diagnosis, Adolescents, Women’s Issues, and Adult General Psychopathology Treatment Groups. Their outcomes-based programs are internationally certified through the Commission on Accreditation of Rehabilitation Facilities (CARF), and are preferred programs for many local insurance companies. Because they are not a hospital-based program, they provide care at the Intensive Outpatient level of care at half the cost of hospital-based programs. In April 2011, KCPPS obtained their first Transcranial Magnetic Stimulation (TMS) device, the first in Kansas City, and in the state of Missouri. Along with treating depression, they have pioneered the utilization of the device in the region for experimental use in treatment of anxiety, psychosis, and migraine headache. Furthermore, their facility has been the driving force behind the acceptance of TMS by regional insurance companies as a covered treatment, under most plans. Future projects for KCPPS include the creation of a day treatment program for PTSD which seeks to utilize exercise, EMDR, Bio-Feedback, TMS, relaxation training, and process groups to address civilian and military PTSD. Secondly, they plan to create a diabetes education and treatment module which utilizes the current American Diabetes Association treatment guidelines on multidisciplinary and psychosocial treatment of diabetes. Lastly, they are developing a novel approach to telemedicine. Born on March 25, 1973 in South Dakota, Dr. Francis obtained a D.O. from Kansas City University of Medicine in 2000. In his spare time he enjoys skiing and soccer. "Love is a medicine for the sickness of the world; a prescription often given, too rarely taken."-Dr. Karl Menninger For further information, contact About Strathmore’s Who’s Who Worldwide Strathmore’s Who’s Who Worldwide highlights the professional lives of individuals from every significant field or industry including business, medicine, law, education, art, government and entertainment. Strathmore’s Who’s Who Worldwide is both an online and hard cover publication where we provide our members’ current and pertinent business information. It is also a biographical information source for thousands of researchers, journalists, librarians and executive search firms throughout the world. Our goal is to ensure that our members receive all of the networking, exposure and recognition capabilities to potentially increase their business. Lees Summit, MO, May 12, 2017 --( PR.com )-- Dr. John A. Francis of Lees Summit, Missouri has been recognized as a Professional Of The Year for 2017 by Strathmore’s Who’s Who Worldwide for his outstanding contributions and achievements in the field of healthcare.About Dr. John A. FrancisDr. Francis is the President and Medical Director of Kansas City Psychiatric & Psychological Services, LLC. KCPPS is a multidisciplinary mental health facility providing an intense outpatient mental health program in Lees Summit, Missouri. With 14 years experience, he oversees the practice and teaches medical students. Dr. Francis provides psychiatric treatment to children, adolescents, and adults. He has specialized training and expertise in treating PTSD, OCD, and severe persistent mental illness of many varieties. He is Board Certified in Psychiatry and affiliated with the American Psychiatric Association.Since starting in private practice, Dr. Francis has endeavored to make patient care effectual, practical and affordable. In 2007, along with his therapist partner, he formed KCPPS which has been a regional leader in innovative treatments and a leader in implementing contemporary and cost effective treatment models. Their Intensive Outpatient Programs have, since their inception, utilized a “therapy first” model, highlighting the paramount importance of the therapist in the patient’s overall treatment. Their IOP modules address Dual Diagnosis, Adolescents, Women’s Issues, and Adult General Psychopathology Treatment Groups. Their outcomes-based programs are internationally certified through the Commission on Accreditation of Rehabilitation Facilities (CARF), and are preferred programs for many local insurance companies. Because they are not a hospital-based program, they provide care at the Intensive Outpatient level of care at half the cost of hospital-based programs. In April 2011, KCPPS obtained their first Transcranial Magnetic Stimulation (TMS) device, the first in Kansas City, and in the state of Missouri. Along with treating depression, they have pioneered the utilization of the device in the region for experimental use in treatment of anxiety, psychosis, and migraine headache. Furthermore, their facility has been the driving force behind the acceptance of TMS by regional insurance companies as a covered treatment, under most plans.Future projects for KCPPS include the creation of a day treatment program for PTSD which seeks to utilize exercise, EMDR, Bio-Feedback, TMS, relaxation training, and process groups to address civilian and military PTSD. Secondly, they plan to create a diabetes education and treatment module which utilizes the current American Diabetes Association treatment guidelines on multidisciplinary and psychosocial treatment of diabetes. Lastly, they are developing a novel approach to telemedicine.Born on March 25, 1973 in South Dakota, Dr. Francis obtained a D.O. from Kansas City University of Medicine in 2000. In his spare time he enjoys skiing and soccer."Love is a medicine for the sickness of the world; a prescription often given, too rarely taken."-Dr. Karl MenningerFor further information, contact www.kcpps.org About Strathmore’s Who’s Who WorldwideStrathmore’s Who’s Who Worldwide highlights the professional lives of individuals from every significant field or industry including business, medicine, law, education, art, government and entertainment. Strathmore’s Who’s Who Worldwide is both an online and hard cover publication where we provide our members’ current and pertinent business information. It is also a biographical information source for thousands of researchers, journalists, librarians and executive search firms throughout the world. Our goal is to ensure that our members receive all of the networking, exposure and recognition capabilities to potentially increase their business. Click here to view the list of recent Press Releases from Strathmore Worldwide


News Article | May 9, 2017
Site: www.businesswire.com

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--H2O.ai, the company bringing AI to enterprises, today announced that it has partnered with IBM to offer its next-generation AI platform, GPU-powered machine learning, and best-of-breed Deep Learning on IBM’s Power® Systems platform. IBM has collaborated with fellow technology industry leaders through the OpenPOWER Foundation to radically redesign the platform at the chip and system levels by incorporating the use of a wide range of accelerators to achieve greater levels of performance than available on traditional commodity servers. IBM’s POWER architecture with the new NVLink™ interface provides an advanced and affordable platform for high performance analytics. The new NVLink™ interconnects seen in IBM Power Systems S822LC (codename: ‘Minsky’) machines open a much wider path between the CPU and GPU, enabling H2O’s next generation AI platform to get maximum performance gains possible. H2O.ai next generation AI software – best-of-breed Machine Learning and Deep Learning that is optimized for GPUs – can now take advantage of IBM’s POWER architecture to provide enterprises with fastest performance possible and the best price-performance advantage for AI computing. IBM customers can also run H2O algorithms through the IBM Data Science Experience platform to manage and collaborate on data science projects. In addition, H2O is also available on the IBM’s Biginsights and IOP platform for enterprises. “H2O’s interpretable, accurate and fast algorithms democratize the monetization of data with AI. IBM Power Systems provides a resilient and highly available computing platform for H2O.AI customers,” said Sri Ambati, CEO and co-founder of H2O.ai. “We are excited to partner with the IBM team to amplify the transformation of the enterprise with AI.” H2O is the standard open-source AI platform of choice for enterprise businesses. More than 9,000 enterprises and a third of the Fortune 500 Companies are using H2O.ai’s open source platform to derive value from data with machine learning and deep learning and receive real-time insights and make actionable decisions. “In 5 years, A.I. will be behind your every decision. We want to put the most powerful AI software in the hands of our customers and H2O is a complementary addition to the IBM PowerAI deep learning software distribution,” said Sumit Gupta, VP, HPC, AI and Analytic at IBM. “H2O running on IBM Power Systems enables enterprises to leverage the best of breed software on IBM’s powerful hardware to get more value of their data.” H2O.ai has enjoyed a banner year so far. Some of H2O’s mission critical applications include predictive maintenance, operational intelligence, security, fraud, auditing, churn, credit scoring, user based insurance, predicting sepsis, ICU monitoring and more. The company was named a Strong Performer in The Forrester Wave™: Predictive Analytics & Machine Learning (PAML) Solutions, Q1 2017 report by Forrester Research in March, a Visionary in Gartner’s February Magic Quadrant and one of CB Insights’ AI 100 in January. For more information about H2O.ai, please visit www.h2o.ai. H2O.ai is focused on bringing AI to businesses through software. Its flagship product is H2O, the leading open source platform that makes it easy for financial services, insurance and healthcare companies to deploy AI and deep learning to solve complex problems. More than 9,000 organizations and 80,000+ data scientists depend on H2O for critical applications like predictive maintenance and operational intelligence. The company -- which was recently named to the CB Insights AI 100 -- is used by 169 Fortune 500 enterprises, including 8 of the world’s 10 largest banks, 7 of the 10 largest insurance companies and 4 of the top 10 healthcare companies. Notable customers include Capital One, Progressive Insurance, Transamerica, Comcast, Nielsen Catalina Solutions, Macy's, Walgreens and Kaiser Permanente. Follow us on Twitter @h2oai. To learn more about H2O customer use cases, please visit http://www.h2o.ai/customers/ Join the Movement.


"The filing acceptance of Luminesse brings us one step closer to bringing a new treatment option to potentially help patients in the more than 14 million households who use OTC eye drops to treat ocular redness," said Joseph C. Papa, Chairman and CEO of Valeant. "If approved, Luminesse may provide patients with ocular redness significant benefits versus other competing redness reliever products currently available." Six clinical studies were conducted to evaluate the safety and effectiveness of low-dose Luminesse in relieving ocular redness, including a study to demonstrate the absence of IOP-lowering potential of low-dose brimonidine. Bausch + Lomb also conducted a comprehensive review of all post-marketing safety data, as the active ingredient brimonidine tartrate is typically found to be used in prescription ophthalmic products. The drug was found to be highly efficacious and safe with low risk of tachyphylaxis (tolerance or loss of effectiveness) and rebound congestion, which are both common to currently available OTC redness reliever eye drops. Luminesse was licensed by Eye Therapies, Inc., to Bausch + Lomb. Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com. Bausch + Lomb, a Valeant Pharmaceuticals International, Inc. company, is a leading global eye health organization that is solely focused on protecting, enhancing and restoring people's eyesight. Its core businesses include over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. Bausch + Lomb develops, manufactures and markets one of the most comprehensive product portfolios in our industry, which is available in more than 100 countries. This press release may contain forward-looking statements which may generally be identified by the use of the words "anticipates", "if approved", "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent annual or quarterly report and detailed from time to time in Valeant's other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes, unless required by law. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bausch--lomb-announces-pdufa-date-for-new-otc-redness-reliever-brimonidine-tartrate-ophthalmic-solution-0025-300453630.html

Loading IOP collaborators
Loading IOP collaborators